Table 3 EZH2 expression levels associated with NSCLC overall survival in TCGA cohort and TJMUGH cohort。
From: EZH2 inhibitors reverse resistance to gefitinib in primary EGFR wild-type lung cancer cells
| Â | Pathological type | Factors | n | Mean survival (Months) | Median survival (Months) | Univariate analysis (P value) |
|---|---|---|---|---|---|---|
TCGA chort | LUAD | Low EZH2 expression | 176 | 96.95 | 50.93 | 0.041 |
High EZH2 expression | 176 | 65.88 | 43.93 | |||
LUSC | Low EZH2 expression | 205 | 75.31 | 61.37 | 0.821 | |
High EZH2 expression | 204 | 74.62 | 65.83 | |||
TJMUGH chort | LUAD | Low EZH2 expression | 8 | 65.77 | 63.25 | 0.393 |
High EZH2 expression | 8 | 48.22 | 32.54 | |||
LUSC | Low EZH2 expression | 12 | 54.03 | 45.21 | 0.152 | |
High EZH2 expression | 12 | 40.48 | 35.57 |